Found 41 articles for: "tofacitinib"
Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreReversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma
June 2022 | Volume 21 | Issue 6 | Case Reports | 671 | Copyright © June 2022
Lichen planopilaris (LPP) is a cicatricial alopecia that presents with patchy or diffuse hair loss at the vertex or parietal scalp. The literature has limited evidence on treatments for this challengi...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MoreTreatment of Alopecia in Children
January 2022 | Volume 21 | Issue 1 | Original Article | 49 | Copyright © January 2022
Alopecia or hair loss in children is an important and often challenging problem to diagnose and treat. Early diagnosis and treatment is the key because hair loss in children has a significant physical...
Read MoreAntihistamines in Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 844 | Copyright © August 2021
Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common a...
Read MoreEvaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast
April 2020 | Volume 19 | Issue 4 | Original Article | 378 | Copyright © April 2020
Background: Patients with moderate-to-severe psoriasis can have symptoms resulting in significant impact on patient-reported outcomes (PROs). The effect of etanercept (ETN) in moderat...
Read MoreGrover’s Disease Treated With Total Skin Electron Beam Radiotherapy
April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019
Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read MoreTreatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019
INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read MoreDisorders of Hypopigmentation
March 2019 | Volume 18 | Issue 3 | Supplement Individual Articles | 115 | Copyright © March 2019
common cause of depigmentation worldwide is vitiligo. This disorder affects 1-2% of the world’s population and is seen in all races. Vitiligo is an autoimmune disorder in which the predominant cause...
Read MoreA Review of the Dermatologic Symptoms of Idiopathic Mast Cell Activation Syndrome
February 2019 | Volume 18 | Issue 2 | Original Article | 162 | Copyright © February 2019
Since the first reported cases in 2007, idiopathic mast cell activation syndrome has been increasingly recognized. Understanding of the cutaneous manifestations of this condition is imperative for der...
Read MoreNavigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules
December 2018 | Volume 17 | Issue 12 | Features | 1330 | Copyright © December 2018
Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis...
Read MoreAn Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review
August 2018 | Volume 17 | Issue 8 | Features | 914 | Copyright © August 2018
KD is an 8 year-old male patient who presented to our clinic in December 2016 with a history of patchy hair loss for many months duration that was worsening. KD’s past medical history was notable fo...
Read MoreSuccessful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
July 2018 | Volume 17 | Issue 7 | Case Reports | 800 | Copyright © July 2018
Alopecia areata is an autoimmune disease involving the hair follicle with a chronic, relapsing course. Tofacitinib...
Read MoreThe Latest Drugs and Small Molecule Inhibitors for Skin and Hair
December 2017 | Volume 16 | Issue 12 | Original Article | 1224 | Copyright © December 2017
Biologic drugs, a novel class of agents engineered to target specifc mediators of infammation, and small-molecule inhibitors that pen-etrate the cell membrane to interact with targets inside a cell...
Read MoreThe Static Physician’s Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis
August 2017 | Volume 16 | Issue 8 | Original Article | 793 | Copyright © August 2017
Introduction: Genital psoriasis is a common but frequently overlooked manifestation of psoriasis with a considerable impact on patients’ quality of life. Currently no validated clinical tria...
Read MoreAggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib
May 2017 | Volume 16 | Issue 5 | Case Reports | 508 | Copyright © May 2017
The Food and Drug Administration approved Ruxolitinib in 2011 for the treatment of primary myelofibrosis. Five-year safety data showed a higher incidence of skin cancer in patients treated with Rux...
Read MoreEvaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2
February 2017 | Volume 16 | Issue 2 | Original Article | 147 | Copyright © February 2017
BACKGROUND: The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE: To evaluate the product of P...
Read MoreEmerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib
August 2015 | Volume 14 | Issue 8 | Original Article | 786 | Copyright © August 2015
BACKGROUND: Increased knowledge of the molecular regulatory mechanisms that contribute to the pathogenesis of psoriasis and other inflammatory diseases has created new opportunities for the developmen...
Read MoreRandomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design
August 2015 | Volume 14 | Issue 8 | Original Article | 777 | Copyright © August 2015
Intra-subject, left-right, randomized, controlled study designs are often used for proof-of-concept studies in dermatology. This design was used to evaluate the safety and efficacy of a topical soluti...
Read MoreEfficacy, Tolerability, and Pharmacodynamics of Apremilast in Recalcitrant Plaque Psoriasis: A Phase II Open-Label Study
August 2013 | Volume 12 | Issue 8 | Original Article | 888 | Copyright © August 2013
BACKGROUND: Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open...
Read More
